Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bullish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $14.65
Key levels
Resistance$12.97
Resistance$10.76
Support$9.14
Support$6.88
Latest news & SEC filings
NewsSyndax Pharmaceuticals gives new CFO Aaron A. Ondrey an inducement stock award
All SNDX news →Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing cancer therapies. Its approved medicines are Revuforj (revumenib), an oral menin inhibitor for certain relapsed or refractory acute leukemias, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody for chronic graft-versus-host disease. The company also runs clinical programs in acute leukemia, myelofibrosis, and idiopathic pulmonary fibrosis. It operates primarily in the United States, with axatilimab co-commercialized alongside Incyte.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
SEPT Low Target
$34.00
SEPT Mid Target
$37.00
SEPT High Target
$43.00
Analyst Consensus
$37.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SNDX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$27.86
15
Moat Score
NONE
1/9
Piotroski Score
-2.9
Altman Z-Score
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Podlesak Dennis | director | Buy | 8,000 | $94K | Oct 29, 2026 |
| Podlesak Dennis | director | Sale | 8,000 | $114K | Oct 29, 2026 |
| Botwood Nicholas A.J. | officer | Buy | 31,235 | $432K | Jun 12, 2026 |
| Botwood Nicholas A.J. | officer | Sale | 31,235 | $567K | Jun 12, 2026 |
| Botwood Nicholas A.J. | officer | Buy | 22,515 | $311K | Jun 11, 2026 |
| Botwood Nicholas A.J. | officer | Sale | 34,280 | $617K | Jun 11, 2026 |
| Goldan Keith A. | officer | Sale | 1,177 | $22K | Jun 1, 2026 |
| Metzger Michael A | director officer | Sale | 6,847 | $130K | Jun 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
627.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
11.56%
FCF Growth YoY
-17.6%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for SNDX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:58:02 | $9.59 | 2,944 | $$28K | SELL |
| 21:15:04 | $9.60 | 68,700 | $$660K | SELL |
| 21:11:39 | $9.60 | 60,600 | $$582K | BUY |
| 21:11:25 | $9.70 | 206,000 | $$2.0M | BUY |
| 21:10:38 | $9.70 | 60,600 | $$588K | BUY |
5 dark pool trades shown · $$3.9M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for SNDX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $11 | Nov 20 | 9 | $$50 | 5 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for SNDX. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $SNDX (Syndax Pharmaceuticals Inc) Price: $21.82 | Zone: $19.92 to $22.05 Conviction: LOW | Analyst upside: +69% Near resistance (89% of range) — breakout watch. Mixed signals (1+ vs 1...
SEPT Brain on $SNDX -- Bearish 'Saudi Arabia launched covert attacks on Iran as regional war widened' - Reuters -- underlying trend leans bearish (45%). Active market event: 'Saudi Arabia launched co...
Join 3,500+ traders discussing SNDX in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Syndax Pharmaceuticals Inc (SNDX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (4 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Syndax Pharmaceuticals Inc (SNDX) is at $9.59, up 1.05% (+$0.10) at the Nov 11, 2026 close.
Latest SNDX news — Nov 9, 2026: Syndax Pharmaceuticals gives new CFO Aaron A. Ondrey an inducement stock award
The average analyst price target for SNDX is $37.00, ranging from $34 to $43, based on 7 analysts. Latest: HC Wainwright & Co. maintains on Nov 3, 2026.
Analyst ratings for SNDX: 0 Buy, 10 Hold, 0 Sell — consensus Hold.
SNDX does not currently pay a dividend.
Support: $9.14, $6.88. Resistance: $10.76, $12.97, $14.65.
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
Nov 9, 2026: Syndax Pharmaceuticals gives new CFO Aaron A. Ondrey an inducement stock award